Yair Herishanu, MD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, comments on the increased risk of infection-related mortality in patients with chronic lymphocytic leukemia (CLL) affected by COVID-19, discussing humoral and T-cell responses to COVID-19 vaccination in these patients. Dr Herishanu explains that response to vaccines in these patients is lower than that of the general population and depends on their current treatment. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.